Physician profile
Michael Biunno
NPI 1083826861
$2,880.33
in general payments reported to CMS, 2019-2025
14 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $317 · 2021: $257 · 2022: $382 · 2023: $824 · 2024: $593 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $886.05 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $478.80 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $344.50 | 2020-2022 | |
| Allergan, INC. | $334.12 | 2019-2020 | |
| Indivior INC. | $251.86 | 2023-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $147.29 | 2020-2023 | Rexulti |
| Alkermes, INC. | $123.91 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $71.52 | 2019-2021 | |
| Braeburn INC. | $60.69 | 2023-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $57.11 | 2019-2020 | |
| Orexo US, INC. | $41.19 | 2019 | |
| Lundbeck LLC | $32.73 | 2022-2023 | Rexulti |
| Corium, LLC | $29.54 | 2023 | Azstarys |
| Shire North American Group INC | $21.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Biunno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.